WASHINGTON, DC, February 11, 2015 – The Alliance for Regenerative Medicine (ARM) today announced it will hold the fifth annual Advanced Therapies Summit on March 12, 2015 in Paris, France. This one-day meeting will bring together top executives and clinical researchers from the advanced therapies community across Europe and the U.S. to foster discussion aimed at furthering the field as a whole.
The Summit’s program will feature high-level interactive talks with leaders of big pharma on the role their corporations play in advancing the field. Additionally, experts and key opinion leaders in translational medicine, regulatory and reimbursement issues will guide discussions focused on broadening the understanding of the advanced therapies sector and the work necessary to continue its growth and success. The Summit will provide extensive networking opportunities with leading international advanced therapies companies.
“Close international coordination is essential to the successful development of the advanced therapies field,” said Edward Lanphier, president and CEO of Sangamo BioSciences and chairman of ARM. “This annual summit provides the opportunity to meet, collaborate with and learn from our global colleagues to forge closer ties and bring important medical advances to patients around the world.”
Mr. Lanphier will kick off the event with a thorough overview of the state of the advanced therapies industry, followed by roundtable discussions on some of the most pressing issues in the field today: cell therapy commercialization; gene therapy in Europe and the U.S.; big pharma’s outlook on advanced therapies; and the role of Europe’s major research institutions in enabling clinical and commercial translation.
Top industry CEOs, senior executives and translational experts will lead the Summit’s roundtable discussions, representing organizations from across the sector, including AbbVie, Celgene Cellular Therapeutics, Cell Therapy Catapult, The Forum for Innovative Regenerative Medicine (FIRM), Fraunhofer Institute for Cell Therapy and Immunology, Genethon, GenSight Biologics, Lysogene, MEDINET, PharmaCell, ReNeuron, TiGenix and more. A finalized agenda and speaker list will be available in the coming weeks.
The event will be held at the Paris Marriott Rive Gauche Hotel & Conference Center located at 17 Boulevard Saint Jacques in Paris, France. Registration is now open – to learn more and to secure a spot, please visit ARM’s event page.
For media interested in attending, please contact Lyndsey Scull (lscull@alliancerm.org) for information regarding complimentary press registration.
About The Alliance for Regenerative Medicine
The Alliance for Regenerative Medicine (ARM) is an international multi-stakeholder advocacy organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine worldwide. ARM also works to increase public understanding of the field and its potential to transform human healthcare, providing business development and investor outreach services to support the growth of its member companies and research organizations. Prior to the formation of ARM in 2009, there was no advocacy organization operating in Washington, D.C. to specifically represent the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today, ARM has more than 200 members and is the leading global advocacy organization in this field. To learn more about ARM or to become a member, visit http://www.alliancerm.org.
# # #
